A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy

被引：6
|
作者：
Fang, Wenfeng [1 ]
Huang, Yihua [1 ]
Gan, Jiadi [1 ]
Hong, Shaodong [1 ]
Zhang, Li [1 ]
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 09期
基金：
国家重点研发计划;
关键词：
D O I：
10.1016/j.jtho.2019.04.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E201 / E202
页数：2
相关论文
共 50 条
  • [21] Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'
    Inagaki, Yuji
    Tamiya, Akihiro
    [J]. LUNG CANCER, 2020, 148 : 179 - 180
  • [22] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
  • [23] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
    Russell, Molly C.
    Garelli, Alyssa M.
    Reeves, David J.
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
  • [24] Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation
    Korkmaz, Levent
    Artac, Mehmet
    Karaagac, Mustafa
    Er, Zehra
    Boruban, Melih C.
    Poyraz, Necdet
    Kaya, Bugra
    Tavli, Lema
    Odev, Kemal
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (01): : 64 - 66
  • [25] Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
    Gao, X.
    Wei, X-W.
    Wu, Y-L.
    Zhou, Q.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [26] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [27] A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer
    van Veggel, Bianca A. M. H.
    van der Wekken, Anthonie J.
    Paats, Marthe S.
    Hendriks, Lizza E. L.
    Hashemi, Sayed M. S.
    Daletzakis, Antonios
    van den Broek, Daan
    Bosch, Linda J. W.
    Monkhorst, Kim
    Smit, Egbert F.
    de Langen, Adrianus J.
    [J]. CANCER, 2024, 130 (05) : 683 - 691
  • [28] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    [J]. PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [29] A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer"
    Veggel, Bianca van
    Langen, Adrianus Johannes de
    [J]. LUNG CANCER, 2020, 148 : 181 - 181
  • [30] Osimertinib in uncommon EGFR exon 21 L861R and EGFR exon 18 deletion-insertion mutant non-small cell lung cancer-case report
    Wang, Yang
    Dorwal, Pranav
    Rajadurai, Suraindra
    Arulananda, Surein
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 434 - 442
12345